Roman Butler Fullerton & Co’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.08M | Sell |
4,372
-220
| -5% | -$47.3K | 0.26% | 96 |
|
|
2026
Q1 | $972K | Buy |
4,592
+52
| +1% | +$11.5K | 0.27% | 94 |
|
|
2025
Q4 | $990K | Sell |
4,540
-7
| -0.2% | -$1.59K | 0.26% | 101 |
|
|
2025
Q3 | $1.02M | Buy |
4,547
+247
| +6% | +$50.3K | 0.27% | 94 |
|
|
2025
Q2 | $818K | Sell |
4,300
-270
| -6% | -$50.2K | 0.24% | 107 |
|
|
2025
Q1 | $808K | Buy |
4,570
+16
| +0.4% | +$3.11K | 0.31% | 79 |
|
|
2024
Q4 | $806K | Sell |
4,554
-207
| -4% | -$38.1K | 0.26% | 97 |
|
|
2024
Q3 | $913K | Buy |
4,761
+9
| +0.2% | +$1.68K | 0.27% | 89 |
|
|
2024
Q2 | $799K | Buy |
4,752
+7
| +0.1% | +$1.16K | 0.26% | 89 |
|
|
2024
Q1 | $797K | Buy |
4,745
+109
| +2% | +$18.8K | 0.3% | 85 |
|
|
2023
Q4 | $762K | Sell |
4,636
-59
| -1% | -$8.6K | 0.3% | 83 |
|
|
2023
Q3 | $695K | Buy |
4,695
+111
| +2% | +$16.3K | 0.33% | 82 |
|
|
2023
Q2 | $631K | Buy |
4,584
+409
| +10% | +$60K | 0.29% | 91 |
|
|
2023
Q1 | $688K | Buy |
4,175
+118
| +3% | +$18K | 0.34% | 90 |
|
|
2022
Q4 | $620K | Buy |
4,057
+18
| +0.4% | +$2.76K | 0.32% | 92 |
|
|
2022
Q3 | $572K | Buy |
4,039
+8
| +0.2% | +$1.15K | 0.36% | 89 |
|
|
2022
Q2 | $619K | Sell |
4,031
-103
| -2% | -$15.7K | 0.34% | 87 |
|
|
2022
Q1 | $670K | Buy |
4,134
+5
| +0.1% | +$726 | 0.31% | 92 |
|
|
2021
Q4 | $559K | Buy |
4,129
+14
| +0.3% | +$1.65K | 0.25% | 104 |
|
|
2021
Q3 | $443K | Hold |
4,115
| – | – | 0.21% | 120 |
|
|
2021
Q2 | $464K | Buy |
4,115
+237
| +6% | +$26.7K | 0.23% | 113 |
|
|
2021
Q1 | $439K | Hold |
3,878
| – | – | 0.22% | 124 |
|
|
2020
Q4 | $416K | Sell |
3,878
-391
| -9% | -$37.6K | 0.25% | 105 |
|
|
2020
Q3 | $374K | Sell |
4,269
-191
| -4% | -$18K | 0.24% | 106 |
|
|
2020
Q2 | $438K | Buy |
4,460
+1,008
| +29% | +$88.8K | 0.31% | 97 |
|
|
2020
Q1 | $263K | Sell |
3,452
-593
| -15% | -$50.5K | 0.23% | 113 |
|
|
2019
Q4 | $358K | Buy |
4,045
+308
| +8% | +$25.6K | 0.24% | 125 |
|
|
2019
Q3 | $283K | Sell |
3,737
-538
| -13% | -$36.9K | 0.2% | 140 |
|
|
2019
Q2 | $311K | Buy |
4,275
+454
| +12% | +$35.7K | 0.21% | 139 |
|
|
2019
Q1 | $308K | Buy |
3,821
+561
| +17% | +$45.9K | 0.22% | 140 |
|
|
2018
Q4 | $288K | Buy |
+3,260
| New | +$287K | 0.24% | 124 |
|
Other funds holding ABBV
Roman Butler Fullerton & Co's ABBV Position: Q2 2026 in Review
Roman Butler Fullerton & Co reduced its AbbVie (ABBV) stake by 4.8% in Q2 2026, selling an estimated $47.3K and leaving 4,372 shares worth $1.08M. The position accounts for 0.26% of the portfolio, ranked #96.
Roman Butler Fullerton & Co first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Roman Butler Fullerton & Co held 4,372 shares of AbbVie worth $1.08M as of Q2 2026.
- Roman Butler Fullerton & Co sold 220 AbbVie shares in Q2 2026, an estimated $47.3K.
- AbbVie made up 0.26% of Roman Butler Fullerton & Co's portfolio in Q2 2026, its #96 holding.
- Roman Butler Fullerton & Co first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Roman Butler Fullerton & Co's 13F filing for Q2 2026, filed 6 Aug 2026.